944-Lecanemab attenuates Alzheimer’sAβ pathology

Paper Talk · May 10, 2026 · 19m

This research explores how the Alzheimer’s drug Lecanemab utilizes microglia to eliminate harmful amyloid-beta (Aβ) plaques from the brain. By utilizing human microglia xenograft models and spatial transcriptomics, scientists discovered that the therapy’s effectiveness depends on its Fc fragment to trigger a specific genetic program in immune cells. This program boosts phagocytosis, improves lysosomal degradation, and increases the expression of SPP1/osteopontin, a protein that directly aids in clearing deposits. Unlike other treatments, Lecanemab appears to reprogram these cells for a…